Warner Chilcott Announces 2008 Financia... (ended December 31 2006; and other risks ...)

Warner Chilcott Announces 2008 Financial Guidance

Date:1/28/2008

ended December 31, 2006; and other risks detailed from time-to-time in our public filings, financial statements and other investor communications.

We caution you that the foregoing list of important factors is not exclusive. In addition, in light of these risks and uncertainties, the matters referred to in our forward-looking statements may not occur. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as may be required by law.

Warner Chilcott Limited

2008 Full Year Financial Guidance

(U.S. dollars in millions, except per share information)

2008 Guidance

Total Revenue(1) $935 to $945

Gross Margin as a % of Revenue 80% to 81%

SG&A Expenses:

Selling & Distribution $93 to $96

A&P $62 to $65

G&A $73 to $76

Total SG&A Expenses(2) $228 to $237

Total R&D Expense $57 to $60(3)

Total Income Tax Provision 7.5% to 8% of EBTA(4)

GAAP Net Income $118 to $128

Cash Net Income ("CNI") $315 to $325(5)

CNI per Share $1.25 to $1.30(5,6)

(1) Our 2008 guidance assumes generic competition for DOVONEX solution in 1Q08 and SARAFEM in 2Q08. Our 2008 guidance does not account for the impact of any future new licensing agreements.

(2) Total SG&A expense does not include any amount that may be payable in connection with the potential settlement of our outstanding legal actions.

(3) Total 2008 R&D consists of internal R&D anticipated to be in the ran
'/>"/>

0

GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Warner Chilcott to Present at the 2008 Wachovia Healthcare Conference
2. Warner Chilcott to Present at the 26th Annual JPMorgan Healthcare Conference
3. Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007
4. Warner Chilcott and NexMed Sign U.S. Collaboration for Topical Alprostadil Treatment for Erectile Dysfunction
5. Virginia Faith Leaders Call on Senators Webb & Warner to Cosponsor Legislation to Protect Kids from Tobacco
6. WellPoint Announces Appearance at Upcoming Conference
7. OPKO Health Announces Changes to Board of Directors
8. NuVasive Announces Preliminary Unaudited Full Year 2007 Financial Results
9. IDEXX Laboratories Announces Fourth Quarter Results
10. U.S. Department of Labor Announces $1.25 Million to North Carolina to Help Trade-Affected Workers Pay for Health Insurance
11. Acura Pharmaceuticals, Inc. Announces Appointment of George K. Ross as Director

Post Your Comments:

Warner Chilcott Announces 2008 Financia...(ended December 31 2006; and other risks ...),Health